Absci Corp Aktie News

Phase‑2‑Studie zur Bewertung von Wirksamkeit und Sicherheit bei Teilnehmerinnen mit chirurgisch diagnostizierter Endometriose und moderaten bis starken endometriose‑assoziierten Schmerzen (EAP) Erwarteter Beginn der Phase‑2‑Studie Mitte 2027 VANCOUVER, Wash. und NEW YORK, 24. September

Bekanntgabe positiver interimistischer Phase‑1‑Daten aus der HEADLINE™-Studie zu ABS-201 Abschluss einer durch Emissionsbanken gezeichneten Emission in Höhe von 100 Mio. USD, einschließlich einer strategischen Investition von 40 Mio. USD durch Eli Lilly & Company Barmittel, Zahlungsmitteläquivalente und marktfähige Wertpapiere reichen nun aus, um den Betrieb bis in die zweite Hälfte 2028 zu fin...

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,...

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: